Healthcare / BiotechnologyBSE
$120.00
+0.45 (+0.39%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 18%
FCF escenarios
weak_data · normalized FCF $-2.8M · quality 44.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
18/100
F
Piotroski
1/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$180M
P/E
52.6x
↑EV/EBITDA
14.7x
↑ROE
2.6%
↑Gross Margin
N/A
•Debt/Equity
N/A
•TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
-0.83x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $3.4M · FCF $-2.8M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Net Income | $3.4M | $3.4M | $12.0M | $473030.00 | $5.6M |
| EBITDA | $5.0M | $5.0M | $16.5M | $971280.00 | $3.8M |
| EPS | 2.28 | 2.28 | 8.00 | 0.32 | 3.73 |
| Cash Flow | |||||
| Free Cash Flow | $-2.8M | $-2.8M | $7.2M | $-6.8M | $-3.3M |
| Returns | |||||
| ROE | 2.6% | 2.6% | 9.4% | 0.4% | 4.8% |
| Valuation | |||||
| P/E | 52.63 | 52.63 | — | — | — |
| EV/EBITDA | 14.65 | 14.65 | — | — | — |
| P/B | 1.37 | 1.37 | — | — | — |
| Growth & Yield | |||||
| EPS Growth | -71.5% | -71.5% | 2400.0% | -91.4% | — |
Returns (%)
3Y implied EPS CAGR
67.2%
EPS terminal req.
$10.65
Spread vs growth
-138.7%
5Y implied EPS CAGR
41.4%
EPS terminal req.
$12.88
Spread vs growth
-112.9%
10Y implied EPS CAGR
24.7%
EPS terminal req.
$20.75
Spread vs growth
-96.2%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-21.3%
Start / end P/E
18.3x → 50.4x
EPS bridge
8.00 → 2.28
Residual
-126.0%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.